BlueCrest Capital Management’s Novartis NVS Stock Holding History

BlueCrest Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,460	Closed	-$298K	–	849
2019 Q1	$298K	Sell	3,460 -1,107	-24%	-$88.9K	0.01%	712
2018 Q4	$351K	Buy	4,567 +398	+10%	+$31K	0.02%	457
2018 Q3	$322K	Sell	4,169 -4,910	-54%	-$363K	0.01%	999
2018 Q2	$615K	Buy	+9,079	New	+$627K	0.02%	727

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

BlueCrest Capital Management's NVS Position: Q2 2019 in Review

BlueCrest Capital Management sold out of Novartis (NVS) in Q2 2019, closing a stake of 3,460 shares — an estimated $298K sold.

BlueCrest Capital Management first reported a position in NVS in Q2 2018 and held it in 4 quarters. The position peaked at $615K in Q2 2018. 1,094 funds tracked by Wall St. Rank hold NVS as of Q2 2019.

BlueCrest Capital Management reported no remaining Novartis position as of Q2 2019 after selling out during the quarter.
BlueCrest Capital Management sold 3,460 Novartis shares in Q2 2019, an estimated $298K.
BlueCrest Capital Management first reported a position in Novartis in Q2 2018 and held it in 4 quarters.
BlueCrest Capital Management's Novartis position peaked at $615K in Q2 2018.
1,094 funds tracked by Wall St. Rank held Novartis as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.